Ironwood Pharmaceuticals Future Growth

Future criteria checks 4/6

Ironwood Pharmaceuticals is forecast to grow earnings and revenue by 67.9% and 11.6% per annum respectively while EPS is expected to grow by 71.4% per annum.

Key information

67.9%

Earnings growth rate

71.4%

EPS growth rate

Biotechs earnings growth	21.3%
Revenue growth rate	11.6%
Future return on equity	n/a
Analyst coverage	Good
Last updated	21 Apr 2024

Recent future growth updates

Recent updates

Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Feb 16

Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential

Jan 31

Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price

Dec 19

Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly

Jul 25

An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued

Apr 18

Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Mar 28

Ironwood Pharmaceuticals: Rinse, Wash And Repeat

Oct 05

These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely

Sep 28

Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh

Jul 29

Ironwood Pharmaceuticals: Undervalued Company With Steady Growth

Sep 27

Here's Why I Think Ironwood Pharmaceuticals (NASDAQ:IRWD) Might Deserve Your Attention Today

Jul 21

Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

Jun 22

Ironwood Pharmaceuticals names Thomas McCourt permanent CEO

Jun 07

Earnings and Revenue Growth Forecasts

NasdaqGS:IRWD - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	581	196	237	309	4
12/31/2025	494	139	186	216	5
12/31/2024	448	106	182	191	6
12/31/2023	443	-1,002	183	183	N/A
9/30/2023	432	-952	227	227	N/A
6/30/2023	427	-917	263	263	N/A
3/31/2023	417	182	290	290	N/A
12/31/2022	411	175	274	274	N/A
9/30/2022	421	168	259	259	N/A
6/30/2022	416	173	265	265	N/A
3/31/2022	422	527	252	252	N/A
12/31/2021	414	528	262	262	N/A
9/30/2021	413	530	249	249	N/A
6/30/2021	413	509	227	227	N/A
3/31/2021	398	143	199	199	N/A
12/31/2020	390	106	167	169	N/A
9/30/2020	399	111	140	145	N/A
6/30/2020	427	97	118	126	N/A
3/31/2020	440	84	88	97	N/A
12/31/2019	428	59	4	11	N/A
9/30/2019	433	19	-12	-8	N/A
6/30/2019	367	-153	-69	-69	N/A
3/31/2019	346	-173	-81	-82	N/A
12/31/2018	347	-194	-71	-71	N/A
9/30/2018	310	-190	-90	-89	N/A
6/30/2018	331	-71	-98	-94	N/A
3/31/2018	315	-108	-108	-104	N/A
12/31/2017	298	-55	-104	-101	N/A
9/30/2017	292	-143	N/A	-110	N/A
6/30/2017	271	-143	N/A	-80	N/A
3/31/2017	260	-121	N/A	-53	N/A
12/31/2016	274	-82	N/A	-26	N/A
9/30/2016	240	-82	N/A	-26	N/A
6/30/2016	213	-96	N/A	-52	N/A
3/31/2016	187	-123	N/A	-71	N/A
12/31/2015	150	-143	N/A	-107	N/A
9/30/2015	134	-166	N/A	-110	N/A
6/30/2015	112	-161	N/A	-123	N/A
3/31/2015	91	-173	N/A	-133	N/A
12/31/2014	76	-190	N/A	-156	N/A
9/30/2014	43	-204	N/A	-175	N/A
6/30/2014	31	-224	N/A	-194	N/A
3/31/2014	34	-229	N/A	-238	N/A
12/31/2013	23	-273	N/A	-273	N/A
9/30/2013	45	-265	N/A	-254	N/A
6/30/2013	136	-155	N/A	-157	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IRWD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: IRWD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: IRWD is expected to become profitable in the next 3 years.

Revenue vs Market: IRWD's revenue (11.6% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: IRWD's revenue (11.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if IRWD's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Ironwood Pharmaceuticals Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Price target decreased by 10% to US$18.50

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Price target increased by 11% to US$19.83

Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for the Fiscal Year 2023 and Provides Earnings Guidance for the Fiscal Year 2024

Consensus EPS estimates fall by 42%

Recent updates

Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)

Price target decreased by 10% to US$18.50

New minor risk - Share price stability

New minor risk - Insider selling

Full year 2023 earnings: EPS misses analyst expectations

Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Fiscal Year 2024

CEO & Director notifies of intention to sell stock

Price target increased by 11% to US$19.83

Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential

Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for the Fiscal Year 2023 and Provides Earnings Guidance for the Fiscal Year 2024

Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price

Consensus EPS estimates fall by 42%

Ironwood Pharmaceuticals, Inc. provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings: EPS misses analyst expectations

Ironwood Pharmaceuticals, Inc. Provids Earnings Guidance for the Year 2023

Ironwood Pharmaceuticals, Inc. Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting

Ironwood Pharmaceuticals, Inc. Presents Positive Final Data from Stars Nutrition, A Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity

Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

Price target increased by 15% to US$16.50

Senior VP recently bought US$300k worth of stock

Ironwood Pharmaceuticals, Inc. Revises Financial Guidance for the Year 2023

New major risk - Negative shareholders equity

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly

Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old

CEO & Director notifies of intention to sell stock

CEO & Director recently sold US$364k worth of stock

Price target increased by 12% to US$14.33

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Ironwood Pharmaceuticals, Inc. Presents Results from Phase III Clinical Trial in Pediatric Patients

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued

CEO & Director notifies of intention to sell stock

Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Senior VP & COO recently sold US$388k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Ironwood Pharmaceuticals, Inc. Provides Financial Guidance for 2023

Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2023

CEO & Director notifies of intention to sell stock

Senior VP & COO recently sold US$335k worth of stock

Senior VP recently sold US$76k worth of stock

Senior VP notifies of intention to sell stock

Third quarter 2022 earnings: Revenues miss analyst expectations

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

CEO & Director notifies of intention to sell stock

Ironwood Pharmaceuticals: Rinse, Wash And Repeat

These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely

Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of Linzess® (Linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation

CEO & Director notifies of intention to sell stock

Senior VP & COO notifies of intention to sell stock

Senior VP & COO recently sold US$342k worth of stock

Consensus EPS estimates fall by 22%

CEO & Director notifies of intention to sell stock

Ironwood Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2022

Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh

CEO & Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Director exercised options and sold US$69k worth of stock

High number of new directors

CEO & Director notifies of intention to sell stock

Ironwood Pharmaceuticals, Inc. to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022

First quarter 2022 earnings: EPS misses analyst expectations